Synthesis, State-of-The-Art NMR-Binding and Molecular Modeling Study of New Benzimidazole Core Derivatives as Pin1 Inhibitors: Targeting Breast Cancer

Samira Nashaat, Morkos A. Henen, Shahenda M. El-Messery, Hassan Eisa

PII:	S0968-0896(20)30316-3
DOI:	https://doi.org/10.1016/j.bmc.2020.115495
Reference:	BMC 115495
To appear in:	Bioorganic & Medicinal Chemistry
Received Date:	15 February 2020
Revised Date:	25 March 2020
Accepted Date:	5 April 2020



Please cite this article as: S. Nashaat, M.A. Henen, S.M. El-Messery, H. Eisa, Synthesis, State-of-The-Art NMR-Binding and Molecular Modeling Study of New Benzimidazole Core Derivatives as Pin1 Inhibitors: Targeting Breast Cancer, *Bioorganic & Medicinal Chemistry* (2020), doi: https://doi.org/10.1016/j.bmc.2020.115495

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.

# Synthesis, State-of-The-Art NMR-Binding and Molecular Modeling Study of New Benzimidazole Core Derivatives as Pin1 Inhibitors: Targeting Breast Cancer

Samira Nashaat,<sup>1</sup> Morkos A. Henen, <sup>1,2\*</sup> Shahenda M. El-Messery,<sup>1\*</sup> Hassan Eisa<sup>1</sup>

<sup>1\*</sup>Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O.Box 35516, Mansoura, Egypt.

<sup>2</sup>\*Department of Biochemistry & Molecular Genetics, University of Colorado, Denver, USA

Corresponding Authors: Dr. Shahenda M. El-Messery & Dr. Morkos A. Henen, Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O.Box 35516, Mansoura, Egypt. E-mail: <u>selmessery@gmail.com</u> <u>morkos.henen@ucdenver.edu</u>\_Tel, Fax: +20-50-2200242

#### Abstract

New series of benzimidazole ring core conjugated with either dithiocarbamate or thiopropyl linkers, hybridized with different secondary amines were synthesized; **5-15** and **22-31**; respectively. The new compounds were characterized by different spectroscopic techniques (<sup>1</sup>H, <sup>13</sup>C 1D & 2D NMR, ESI-MS and IR). They were screened for *in vitro* anticancer activity against breast cancer using MCF7 cell line. The results obtained revealed that compounds **5**, **12**, **15** and **25** were the most active among the synthesized series exhibiting IC<sub>50</sub> < 10 µg/ml against DOX. To characterize targeting breast cancer on molecular level, binding to <sup>15</sup>N-labeled Pin1 enzyme was conducted using state-of-the-art 2D NMR binding experiments. Results showed promising binding between compounds **5**, **12**, and **25** by chemical shift perturbation (peak shifting or peak disappearance). Molecular docking study were quite valuable to explain the binding mode of active derivatives *via* hydrogen bonding. Additional contact preferences and surface mapping studies stated the similarity pattern between active candidates which may pave the way for more precise anti breast cancer target optimization.

# Keywords

Benzimidazole, breast cancer, NMR, <sup>15</sup>N-<sup>1</sup>H HSQC, Pin1 Inhibitors

## 1- Introduction

Cancer is one of major health problems in the world. It is characterized by abnormal cell growth and may have the potential to invade other parts of body (metastasis). One of the most common cancer types is breast cancer which causes death to millions of women every year (it affects one in eight women in the US). So there is an imperative need for discovering more effective drugs to treat breast cancer [1]. Different classes of heterocyclic compounds have been studied as anticancer agent, one of the most important heterocyclic compounds are benzimidazoles due to their versatile biological activity, such as anti-inflammatory [2], antiviral [3, 4], antibacterial [5, 6], antifungal [7-9], antioxidant [10, 11] and anti-proliferative/anticancer activities [12, 13]. Special attention will be highlighted on benzimidazoles as anticancer agents against breast cancer (chart 1) [14-19].

On the other hand, dithiocarbamates are organosulphrus compounds with variable biological activities, such as antibacterial, antifungal, antiviral including HIV and anticancer. Their antitumor activity due to their metal binding properties resulting from presence of two Sulphur atoms, which have the ability to donate a lone pair of electrons to central metal atom to form stable metal complex [20-23]. It was reported that linking benzimidazole with dithiocarbamate moieties results in compound with improved anticancer activity [24].

Human Pin1 (protein interacting with NIMA "never in mitosis gene a") is a member of the family of peptidyl-prolyl cis-trans isomerase. Pin1 isomerizes the phosphorylated S/T-P motif, which results in a conformational change in the target protein [23]. Other members of the same family include FKBP and Cyclophilin. Pin1, regulates a large variety of proteins, especially those involved in mitosis. Downstream effects of substrate isomerization by Pin1 include conformational changes in the phosphorylation state, and stability/turnover of the substrate [24,25]. The conformational regulation catalyzed by Pin1 has a profound impact on key proteins involved in the regulation of cell growth, genotoxic and other stress responses, the immune response, induction, and maintenance of pluripotency, germ cell development, neuronal differentiation, and survival. Pin1 binds to estrogen receptor where it performs a regulatory effect on the disordered AF1 of estrogen receptors alpha [26]. It's also reported that Pin1 increases the DNA binding to ER. Therefore, misregulation and overexpression of Pin1 are common in various cancers, particularly breast cancer.

Molecular targeting protocol for cancer treatment is distinct from conventional chemotherapy in terms of higher tumor specificity. One particular molecular target of high potential is Pin1. Pin1 substrate proteins are important in cell cycle regulation, and it's up regulation lead to wide variety of human cancers making Pin1 a potential target for anticancer therapy [24]. It is composed of two domains: *N*-terminal bounded to ww-domain which is responsible for substrate recognition and a catalytic *C*-terminal PPIase domain which is responsible for peptidyl-prolyl isomerase activity [26].

As an important target for cancer, many studies have been pursued to design novel antitumor drugs that specifically inhibit the over-activation of Pin1. NMR-based fragment screening has been reported to target Pin 1 where a large library of small fragments has been tested [27]. Two competitor ligands had been identified where their binding to the Pin1 active site had been verified by crystallography: The D-peptide inhibitor, and the phenylalaninol phosphate. Moreover, NMR screening identified five competitively binding compounds, of which the indole 2-carboxylic acid was the most potent inhibitor of Pin1 (compound 1).

More Importantly, Potter *et al* identified a series of new benzimidazole derivatives as inhibitors of PPIase activity of Pin 1 with high activity (compound 2), Chart 2 [28]. Moreover benzimidazoles class of Pin1 inhibitors have been characterized as potent non-phosphate, small molecular Pin1 inhibitors (sub-micromolar Ki values) *via* interactions with Pin1 catalytic site by the hydrogen bonds between the two nitrogen atom (N,NH) of benzimidazole and the cys 113 thiol and the ser154 alcohol , and interaction also between fused ring system of benzimidazole with hydrophobic pocket [29].

• Why NMR for Drug-Design:

NMR is considered one of the leading applications in drug-Screening because of the high sensitivity, in addition to the possibility to detect the binding site(s) on an atomic level. Many NMR techniques may be applied and are classified in two categories: Ligand-Based and Protein-Based methods [30]. It's one of the known concepts in fragment-based drug design that the compounds to start with are having weak affinities, then they can be optimized using growing or hybridization approaches. Therefore, the use of a sensitive technique like NMR is a must in these cases. In our approach here, we used <sup>15</sup>N-<sup>1</sup>H-HSQC to test the interaction between two novel benzimidazole derivatives and Pin1 [31]. NMR proved very promising to

detect binding. The only challenge, in this case, was the solubility of the new compounds and the need to keep the protein in a reasonable amount of aqueous buffer. We tested only three compounds because of the limited solubility of the others.

In summary, the core of our work is based on combining synthetic techniques, computer aided modelling, NMR and cell-based assays to design new benzimidazole derivatives that harbor higher potency against breast cancer. Compounds 1 and 2 have led the way for us for further optimization towards higher efficient benzimidazole derivatives. We synthesized new hybrid compounds that comprised both benzimidazole and amines linked *via* either dithiocarbamate or thiopropyl linkers and we tested the newly synthesized compounds against breast cancer. In order to look deeper on the molecular level, our work utilize new tool for testing binding affinity depending on NMR methodology technique to study binding to Pin1 as a potential target for antibreast cancer compounds. We believe that our results will pave the way for further studies targeting breast cancer using benzimidazole as a pharmacophore. Moreover, our study will shade the light on using NMR technique in drug design.

## 2- Results and Discussion

## 2.1 Chemistry

The target compounds in this work were prepared *via* two schemes. The reaction of phenylene diamine derivatives with chlorocetic acid according to reported procedure to yield intermediate compounds **3**, **4** [9,13] (scheme 1). The newly synthesized benzimidazoledithiocarbamate-amine conjugates **5-15** were obtained in one pot reaction *via* two steps. Firstly, different substituted secondary amines were mixed with carbon disulphide in dry dimethyl formamide followed by reaction of the resultant product with intermediates **3** and **4** producing compounds **5-15** (Scheme1, Table 1). The structure of the synthesized compounds have been confirmed by different spectroscopic techniques including IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and MS. Compounds **5-15** have shown characteristic thiocarbonyl band at 950-1050 cm<sup>-1</sup> proving the incorporation of DTC group in all the compounds **5-15** clearly proves the incorporation of different amine moieties. Appearance of morpholine protons of compound **5** was shown in the form of a set of multiplet protons at 2.34-3.50 ppm. On the other hand, for compounds **8** & **9** piperazine protons have been appeared as two sets of singlet protons at 2.4 and

3.1 ppm, the same case was reported for piperidine protons of compound **12** at 3.5 and 4.2 ppm. For compounds **10** &**15**, the structures were verified using <sup>13</sup>C-<sup>1</sup>H HMBC [34] and <sup>13</sup>C-<sup>1</sup>H HSQC [35] experiments on BRUKER 600MHz NMR spectrometer. HMBC shows the long-range bond correlation between <sup>13</sup>C and <sup>1</sup>H nuclei while HSQC is doing the opposite by showing the direct one bond correlation between the two nuclei. Overlay of HMBC and HSQC spectra verified the structure of both compounds **10** &**15** by showing the one bond and longer-range correlation. The peaks that have been used to verify the structure are annotated in figure 1.

In scheme 2, The target compounds **21-31** were prepared. Firstly benzimidazole-2-thiol derivatives **18 & 19** were obtained according to reported procedure <sup>14</sup> then they were alkylated by reaction with 1-bromo-3-chloropropane in the presence of potassium carbonate to get the crude intermediates **20, 21** which were further purified by recrystallization to get pure products. The incorporation of *S*-propyl chloro substituent was carried out *via*  $S_N2$  reaction. The final amine-linked benzimidazole thiopropyl derivatives **22-31** were obtained by reaction of compounds **20 & 21** with a series of amines in DMF. The structure of the synthesized compounds have been confirmed by different spectroscopic techniques including <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and MS. <sup>1</sup>H-NMR spectral data for compounds **22-31** clearly proves the incorporation of different amine moieties, also proves the presence of thiopropyl alkyl chain, in which compounds **21-31** displayed three signals as follows: the *S*-CH<sub>2</sub> group appeared as triplet at 3.75-4.39 ppm , N-CH<sub>2</sub> group appeared as triplet at 3.29-3.37 ppm and CH<sub>2</sub> group appeared as pentet at 2.3 ppm.

In compound **22**, morpholine protons appeared in the form of a set of multiplet protons at 2.4-3.50 ppm, while in compound **25**, **26**, piperazine protons appeared in the form of a set of multiplet protons at 2.8-3.14 ppm. In compound **25**, the piperazine attached to methoxy phenyl moiety which appeared as singlet proton at 3.67 ppm, while in compound **26** the piperazine attached to ethoxy phenyl moiety displayed two signals as follows: the  $CH_3$  group appeared as triplet at 1.32 ppm and  $OCH_2$  group appeared as quartet at 4.1 ppm.

# 2.2 In vitro antitumor activity

All the newly synthesized compounds were evaluated for their *in vitro* anticancer effect via the standard MTT method [36-37], against a breast cancer cell line (MCF-7). MTT is a calorimetric assay that is based on the ability of live but not dead tumor cells to reduce yellow

MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by mitochondrial dehydrogenases to purple formazan. **DMSO** is added to dissolve the purple formazan then it's quantified by measuring absorbance at certain wavelength. The amount of formazan produced is quantified using a dose response curve for compounds-treated vs untreated cells to report on the effectiveness of the compounds. The obtained results revealed that the tested compounds **5**, **12**, **15**, and **25** exhibited very strong potency against tested breast cancer cell line (**Figure 2**) in which the compound **15** exhibited the most active candidate with IC<sub>50</sub> at 5.58 µg/ml compared to Doxurubucin (reference IC<sub>50</sub> at 4.17 µg/ml). Moreover, compounds **7**, **8**, **10** and **28** have shown strong activity with IC<sub>50</sub> ranging from 10-20 µg/ml. Compounds **6**, **9**, **, 21**, **26**, **29**, and **30** showed moderate activity against the same cell line with IC<sub>50</sub> 42.75 ,30.47, 46.03, 24.07, 32.73, 27.73, 38.46 µg/ml respectively. On the other hand, compounds **22**, **23**, and **24** showed lowest potency in which **24** exhibited least inhibitory activity with IC<sub>50</sub> at 91.96 µg/ml.

# 2.3 Apoptosis analysis of compound 15

Based on the results from cell-based assay and NMR binding to Pin1, we chose compound **15** to further assess its effect on the apoptotic process. Mcf7 cells were treated with compound **15** for 24 hours and processed for flow cytometry and the presence of Annexin V-FITC/PI was investigated. As shown in table 3, cells treated with compound **15** are showing higher DNA content at the G2-M phase (27.86% vs 5.47% for the control) indicating cell growth arrest at this phase. Moreover, cells treated with compound **15** showed a high percentage apoptosis rate (27.28% vs 1.04% for the control) corresponding to the sum of the percentage of Annexin V-positive/PI-negative staining and double-positive staining cells (early and late apoptosis, respectively).

# 2.4 2D <sup>15</sup>N-<sup>1</sup>H HSQC NMR

2D <sup>15</sup>N-<sup>1</sup>H HSQC NMR is a very sensitive technique to detect binding between specific biomolecule and a small ligand. Not only it can report about binding or not, HSQC spectra can also report about the time regime of exchange between free and bound form if there's binding. Slow exchange leads to the appearance of two sets of peaks corresponding to free and bound form, while intermediate exchange causes peaks broadening due to the µs-ms time scale of exchange. On the other hand, the fast exchange leads to averaging and consequently peaks

shifting (chemical shift perturbation). Herein, we used <sup>15</sup>N- labeled Pin1 enzyme where we recorded HSQC spectra of the protein alone and in the presence of excess amount of three of the newly synthesized compounds. In our research, the main challenge we faced was the solubility of the compounds in a balanced mixture of the protein aqueous buffer. Despite the fact that the compounds were freely soluble in DMSO, it's inapplicable to use pure DMSO to dissolve the protein since this will result in protein denaturation and probably aggregation. Therefore, only three compounds were tested where we were able to get these compounds to dissolve partially in a mixture of 95% buffer and 5% DMSO. In addition, as a control, the spectrum was recorded only in presence of DMSO and compared to the ones with the ligand. The proportion of Pin1 to the compounds was adjusted to be 1:10. The recorded spectra showed chemical shift perturbation for some of the amino acids in the protein (CSP). Chemical shift perturbation and peak shifting is indicative of fast exchange between free and bound states which results in peaks positions averaging. Moreover, some peaks corresponding to different amino acids showed peak disappearance upon binding. This peak disappearing indicated exchange on the us-ms time scale (Figure 5). Furthermore, our NMR results have been verified using cell lines.

# 2.5 Structure Activity Relationship

From the obtained results in table 2, some points can be highlighted about the synthesized compounds activity. Generally, compounds with dithiocarbamate linkage in scheme1 are more potent than compounds with alkyl chain linkage in scheme 2. Compounds **8**, **10**, **15**, and **25** with bulky amines like methoxyphenylpiperazine and ethoxyphenylpiperazine showed higher cytotoxic activity. Compound **22** with morpholine amine showed low cytotoxic activity while compounds **6** and **12**, which have piperidine, showed moderate cytotoxic activity. Changing the substitution at positions 5 and 6 of benzimidazole nucleus did not have a significant effect on the activity of compounds in schemes 1 and 2.

# 2.6 Molecular modeling study

# 2.6.1 Conformational analysis

Conformational analysis for compounds **5**, **12** and **25** have been performed. The best energy conformers were obtained by conformational searching using multiconformer method (**Fig 6**). Further in-depth docking study was performed for the aforementioned compounds which showed good binding to Pin1 enzyme *via* NMR biding technique.

# 2.6.2 Molecular Docking study

The benzimidazole derivative cocrystallized in Pin1 crystal structure obtained from protein data bank (pdb: 4TYO) was chosen as a reference for our docking study due to the similarity of its benzimidazole ligand core structure to our compounds **[38].** This reference ligand showed a tight binding *via* the interaction with a network of hydrogen binding with Arg 69, Lys63, and Cys113 in addition to cationic hydrogen binding with both Phe134 and Ser115 residues **(Fig. 7)**. It was reported that the interaction with Lys63 is essential for Pin1 inhibition **[38].** 

Compound **5** is well-positioned to interact with Lys63, Arg69, Cys 113 and Ser 114 amino acid residues *via* sulpher atom of thiocarbonyl group (**Fig. 8**, left side). Also, compound **12** retains good stacking against the shelf-like hydrophobic surface and occupies a similar position to the benzimidazole ring of cocrystallized ligand by binding to Cys 113 and Lys 63 via hydrogen bonding interaction (**Fig. 8**, right side).

Compound **25** has shown both hydrogen bonding and n-cationic interactions to Ser 114, Gln 131, Gln 129 and Arg69 respectively (**Fig. 9a**). The aligned conformation of compound **25** in binding site was aligned completely inside the binding site surface map explaining its activity experimentally determined by NMR binding technique (**Fig. 9b**).

# 2.6.3 Contact Preference:

The purpose of the Contact Statistics application is to calculate, from the 3D atomic coordinates of ligand, preferred locations for hydrophobic and hydrophilic ligand atoms. In particular, the aim of this work was to study the interactions between the chemical components of the ligands and the protein microenvironment surrounding them. The results obtained indicate that the information underlying the fragment contacts is valuable as it clearly demonstrates the similarity pattern of distribution of the hydrophobic and hydrophilic sites between our ligands **5**, **12** and **25** (shown in **Fig. 10**) and can also be exploited in understanding results of molecular docking simulations. A better understanding of the interaction patterns of these moieties can lead to improved application of ligand binding prediction, protein function recognition, and drug design tools.

# 2.6.4 Surface Mapping

In additional confirmatory investigation step to ensure the similarity between our active candidates' binders to Pin1 enzyme surface mapping study was performed for the conformers with lowest energy. **Figure 11** showed nearly typical surface mapping contours of selected ligands. Hence, that could be contributing to their good binding to our selected enzymes and put more evidence that their compounds anti-breast cancer activity may be attributed to Pin1 inhibition.

## **3-** Conclusion

A new series of benzimidazoles core compounds with dithiocarbamate and thiopropyl link conjugated with different secondary amines were designed, synthesized and biologically evaluated for their antibreast cancer activity using MCF7 cell line. Pin 1 enzyme was chosen as a new goal for breast cancer targeting. Results revealed that compounds **5**, **12**, **15 and 25** were the most potent antibreast cancer activity with  $IC_{50}$  5.70 9.55, 5.58 and 6.84 µg/ml respectively. Using 2D <sup>15</sup>N-<sup>1</sup>H HSQC NMR experiments, we were able to show that the three compounds are binding to the purified Pin1 on a fast time scale. The binding has been proved by noticing the chemical shift perturbation and peak disappearance of some peaks in the 2D NMR spectra. This change is some of the peaks upon binding indicates change in the chemical environment of the corresponding residues as a result of binding. Compounds with dithiocarbamate linkage were more potent than compounds with alkyl chain linkage. Molecular modeling study was conducted to understand the compounds binding to Pin 1, docking study proved a similar binding mode of our compounds to reference co-crystallized ligand to Pin 1 enzyme. Contact statistics and surface map studies stated the similarity between active candidates which assures their fitting to active site of Pin 1 enzyme.

# 4- Experimental Section

The synthesis of the designed compounds was performed in Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. The *in vitro* anticancer screening was conducted in Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Melting points (°C) were determined on Mettler FP80 melting point apparatus and are uncorrected. All of the new compounds were analyzed for C, H and N and agreed with the proposed structures within  $\pm$ 0.4% of the theoretical values. 1D <sup>1</sup>H- and <sup>13</sup>C-NMR were recorded on a JOEL 500 MHz & BRUKER 400 MHz FT spectrometers; chemical shifts are expressed in  $\delta$  ppm with reference

to TMS. For samples **10** & **15** <sup>13</sup>C-<sup>1</sup>H HMBC and HSQC were measured on a shielded BRUKER 600 MHz FT spectrometer in University of Colorado, Denver, USA. The following parameters were used: 64 scans with 2 seconds interscan delay and 4096 points in the <sup>1</sup>H dimension vs 512 points in the <sup>13</sup>C dimension. For samples **23**, **24** and **30**, <sup>13</sup>C-APT NMR (Attached proton test) and 1D-<sup>13</sup>C NMR were performed on BRUKER 600 MHz – cryoprobe-FT spectrometer in University of Colorado, Denver, USA. For APT experiments, 65536 points were recorded, with 256 scans and a relaxation delay of 2 seconds. The H-C J-coupling value was sat to 145 Hz. For the 1D-<sup>13</sup>C NMR, 65536 points were recorded, with 1024 scans and a relaxation delay of 2 seconds.

Mass spectral (MS) data were obtained on a Perkin Elmer, Clarus 600 GC/MS and Joel JMS-AX 500 mass spectrometers. Thin layer chromatography was performed on precoated (0.25 mm) silica gel  $GF_{254}$  plates (E. Merck, Germany), compounds were detected with 254 nm UV lamp. Silica gel (60–230 mesh) was employed for routine column chromatography separations. All the fine chemicals and reagents used were purchased from Aldrich Chemicals Co, USA. Molecular docking experiments were performed using 'Molecular Operating Environment' software on Core i7 workstation.

# 4.1. Chemistry

*4.1.1.* General procedure for preparation of (5,6-dimethyl-1H-benzo[d]imidazol-2-yl)methyl substituted-1-carbodithioate) or (5,6-dichloro-1H-benzo[d]imidazol-2-yl)methyl substituted-1-carbodithioate) **5-15** 

A solution of the appropriate secondary amine (0.05M) in dry DMF (10ml) and carbon disulfide (0.1M) was stirred for 2hr at room temperature, dry  $K_3PO_4$  (0.05M) was add to the reaction mixture and stirred for 3hr at room temperature. 2-(chloromethyl)-5,6-dimethyl-1H-benzo[*d*]imidazole **3** or 5,6-dichloro-2-(chloromethyl)-*1H*-benzo[d]imidazole **4** (0.05M) were added to the reaction mixture, and continuously stirred at room temperature for 1-2 days. After completion of the reaction, which was monitored by TLC, the reaction mixture was poured onto crushed ice and the resulting precipitation was collected by filtration and purified by recrystallization from ethanol.

4.1.1.1. (5,6-dichloro-*1H*-benzo[d]imidazol-2-yl)methyl morpholine-4-carbodithioate **5**: puff solid, IR(KBr, cm<sup>-1</sup>): 800(C-Cl), 1238(C=S), 3400(N-H), <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 2.21-2.32(m,8H,morphorine-*H*), 4.7(s,2H,*S*-CH<sub>2</sub>), 5.5(s,1H,N-H), 7.3(s, 1H, CH benzimidazole), 7.53(s, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ: 35.6, 49.9, 64.5, 118.3, 130.6, 138.2, 142.5, 198.1, MS m/z(%):362.29, calcd.362.3

*4.1.1.2.* (5,6-dichloro-*1H*-benzo[*d*]imidazol-2-yl)methyl piperidine-1-carbodithioate **6:** Gray solid ,, MS m/z(%):360.32, <sup>1</sup>H-NMR(DMSO-d<sub>6</sub>) δ: 2.49(S,1H,NH), 3.89(S,5H,piperidine-H), 4.2(*s*,5H,piperidine-H), 4.9(S,2H,CH2), **7.3**(s, 1H, CH benzimidazole), **7.53**(s, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ: 14.8, 23.4, 26.1, 43.1, 51.3, 64.6, 108.5, 114.5, 119.3, 120.5, 121.8, 123.1, 138.6, 143.7, 147.1, 162.8, MS m/z(%): 160.8(88), 266, 268, calcd.360.32

4.1.1.3.(5,6-dichloro-*1H*-benzo[*d*]imidazol-2-yl)methyl diethylcarbamodithioate )7 Puff solid, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 1.18(t, 3H, CH<sub>3</sub>), 1.24(t, J=7.2Hz, 3H, CH<sub>3</sub>), 3.78(q, 2H, CH<sub>2</sub>), 3.96(q, 2H, CH<sub>2</sub>), 4.75(s, 2H, S-CH<sub>2</sub>), 7.79(s, 2H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSOd<sub>6</sub>) δ: 15.2, 35.8, 48.7, 116.9, 130.2, 139.1, 140.8, 197.9, MS m/z(%):348.30, calcd.348.3

4.1.1.4. (5,6-dichloro-*1H*-benzo[d]imidazol-2-yl)methyl 4-(2-ethoxyphenyl)piperazine-1carbodithioate **8** Puff solid, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.36(t, **J**=6.4Hz, 3H, CH<sub>3</sub>), 2.7(s, 2H, piperazine-H), 2.89(s, 2H, piperazine-H), 3.1(s, 4H, piperazine-H), 4.07(q, 2H, O-CH<sub>2</sub>), 4.82(s, 2H,S-CH<sub>2</sub>), 6.88(s, 1H, CHbenzimidazole), 6.94 (s, 1H, CHbenzimidazole), 7.7-7.8(m, 4H, Ar-H), 12.7(s,1H, NH),<sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) $\delta$ : 16.1, 34.9, 50.1, 51.6, 63.9, 112.7, 117.3, 120.9, 121.2, 121.6, 129.8, 139.2, 141.2, 142.8, 160.9, 197.8 MS m/z(%):481.45, calcd.481.5

4.1.1.5. (5,6-dichloro-*1H*-benzo[*d*]imidazol-2-yl)methyl 4-methylpiperazine-1-carbodithioate **9** Brown solid, IR(KBr, cm-1): 865(C-Cl), 1227(C=S), 3447(N-H), <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 2.39(s, 4H, piperazine-H), 2.49(s, 3H, N-CH<sub>3</sub>), 3.91(s, 2H, piperazine-H), 4.21(s,2H,piperazine-H), 4.78(s,2H,S-CH<sub>2</sub>), 7.7(s, 1H, CHbenzimidazole), 7.8(s, 1H, CHbenzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ :33.9, 45.9, 50.1, 52.9, 117.1, 127.9, 138.6, 140.9, 196.8, MS m/z(%):375.33, calcd.375.3

4.1.1.6. (5,6-dichloro-1H-benzo[d]imidazol-2-yl)methyl 4-(4-methoxyphenyl)piperazine-1carbodithioate **10** Brown solid, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.13(s,4H,piperazine-H), 3.67(s,3H,O-CH<sub>3</sub>), 4.07 (s,2H,piperazine-H), 4.36(s,2H,piperazine-H), 4.8(s,2H,S-CH<sub>2</sub>), 6.82(d, J=8Hz,2H, Ar-H), 6.92(d, J=8.2Hz, 2H,Ar-H), 7.72(s, 1H, CHbenzimidazole), 7.82(s, 1H, CHbenzimidazole), 12.7(s, 1H, NH), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ :34.8, 50.3, 51.7, 58.2, 116.1, 116.2, 117.3, 129.1, 138.9, 141.3, 144.4, 152.2, 197.9, MS m/z(%): 467.43, calcd.467.4

4.1.1.7. (5,6-dichloro-*1H*-benzo[*d*]imidazol-2-yl)methyl 4-(2-chlorophenyl)piperazine-1carbodithioate **11** Brown solid , IR(KBr, cm-1 ):836(C-Cl), 1224(C=S),3422(N-H), <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.37(s,4H,piperazine-H), 4.07(s,2H,piperazine-H), 4.34(s,2H,piperazine-H), 4.81(s,2H,S-CH<sub>2</sub>), 6.8 (d, J=7.5Hz, 1H, Ar-H), 6.86 (s, 1H, Ar-H), 6.94 (d, J=8.1Hz,1H, Ar-H), 7.22(t, J=8Hz, 1H, Ar-H), 7.72(s, 1H, CH benzimidazole), 7.82(s, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 23.7, 25.1, 34.8, 51.4, 113.5, 126.1, 134.9, 143.8, 192.5 , MS m/z(%):471.84, calcd.471.9

4.1.1.8. (5,6-dimethyl-*1H*-benzo[*d*]imidazol-2-yl)methyl piperidine-1-carbodithioate **12** Puff solid , m.p.=188°c , yield=15% , IR(KBr, cm-1 ): 1234(C=S) , 3449(N-H), <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.57(s,3H,CH<sub>3</sub>), 1.64(S,3H,CH<sub>3</sub>), 2.49(s,2H,piperidine-H), 3.89(s,4H,piperidine-H), 4.2(s,4H,piperidine-H),4.08(S,2H,CH<sub>2</sub>), **6.8(s**, 1H, CHbenzimidzole), 7.3(s, 1H, CHbenzimidazole), 12.12(S,1H,NH), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ :17.9, 23.7, 23.9, 33.9, 50.9, 116.8, 128.9, 137.1, 140.5, 199.9 MS m/z(%): 319.49, calcd.319.5

4.1.1.9. (5,6-dimethyl-*1H*-benzo[*d*]imidazol-2-yl)methyl 4-(4-methoxyphenyl)piperazine-1carbodithioate **13** Puff solid , m.p.=104°c , yield=15%, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.14(s,3H,CH<sub>3</sub>), 1.22(s,3H,CH<sub>3</sub>), 3.12(s,4H,piperazine-H), 3.67(s,3H,O-CH<sub>3</sub>), 4.02(s,2H,piperazine-H), 4.37(s,2H,piperazine-H), 4.72(s,2H,S-CH<sub>2</sub>), 6.82(d, J=8Hz,2H, Ar-H), 6.92(d, J=8.2Hz, 2H, Ar-H), 7.22(s, 1H, CH benzimidazole), 7.27(s, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ :18.6, 34.2, 50.9, 51.8, 57.8, 115.8, 116.2, 129.7, 136.9, 140.9, 145.9, 156.1, 198.1, MS m/z(%):426.6, calcd.426.6

4.1.1.10. (5,6-dimethyl-1H-benzo[*d*]imidazol-2-yl)methyl 4-(2-chlorophenyl)piperazine-1carbodithioate **14** Puff solid, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 1.05(s,3H,CH<sub>3</sub>), 1.17(s,3H,CH<sub>3</sub>), 2.38 (s,4H,piperazine-H), 4.02(s,2H,piperazine-H), 4.37(s,2H,piperazine-H), 4.729(s,2H,S-CH<sub>2</sub>), 6.8 (d, J=7.5Hz,1H, Ar-H), 6.88(d, J=8.1, 1H, Ar-H), 6.93(s, 1H, Ar-H), 7.237(t, J=8Hz, 1H, Ar-H), 7.27(s, 2H, CH benzimidazole), 12.16(S,1H,NH), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:18.2, 34,8, 51.9, 52.8, 116.3, 124.1, 125.1, 128.8, 129.9, 130.1, 130.7, 136.7, 140.8, 148.6, 196.2, MS m/z(%):431.01, calcd.431

4.1.1.11. (5,6-dimethyl-1H-benzo[*d*]imidazol-2-yl)methyl 4-(2-ethoxyphenyl)piperazine-1carbodithioate **15** Yellow solid, IR(KBr, cm-1):1236(C=S), 3421(N-H) <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.34(t, **J**=6.75Hz, 3H,CH<sub>3</sub>), 2.2(s,3H,CH<sub>3</sub>), 2.3(s,3H,CH<sub>3</sub>), 3.09(q,2H,O-CH<sub>2</sub>), 4.002-4.05 (m,8H,piperazine-H), 4.37(s,1H,NH), 4.7(s,2H,S-CH<sub>2</sub>), 6.85-6.95(m, 4H, Ar-H), 7.3(s, 1H, CH benzimidazole), 7.4(s, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ :16.1, 18.5, 34.5, 52.3, 53.1, 61.2, 112.2, 116.8, 120.7, 121.3, 121.9, 129.9, 138.9, 140.9, 142.1, 160.3, 197.9, MS m/z(%):440.62, calcd.440.6

*4.1.2.* General Procedure for preparation of 2-((3-chloroprpyl)thio)-1H-benzo[d]imidazole **20** and 5-chloro-2-((3-chloropropyl)thio)-1H-benzo[d]imidazole **21** 

In 50 ml rounded-bottomed flask the 1H-benzo[*d*]imidazole-2-thiol **18** or 5-chloro-1Hbenzo[d]imidazole-2-thiol **19** (0.005 mol) was added with 1-bromo-2-chloroethane(0.005 mol) and unhydrous  $K_2CO_3$  (0.0075 mol) in 20 ml dry DMF and stirred at room temprature for 1 hr. After compleation of the reaction which was monitored by TLC, water was added to the reaction mixture and the resulting ppt was collected by filtration to give the titled compounds.

4.1.3. General Procedure for preparation of 2-((3-(substituted-1-yl)propyl)thio)-1H-benzo[d]imidazole or 5-chloro-2-((3-(substituted-1-yl)propyl)thio)-1H-benzo[d]imidazole 22-31

<sup>4.1.2.1 (5-</sup>chloro-2-((3-chloropropyl)thio)-1H-benzo[*d*]imidazole) **21** puff solids , m.p. =130, <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 2.16(p, 2H,CH<sub>2</sub>), 3.37(t, **J**=6.75Hz, 2H, N-CH<sub>2</sub>), 3.75(t, **J**=6.5Hz, 2H, S-CH<sub>2</sub>), 7.15(d, **J**=8Hz, 1H, CH benzimidazole), 7.4(d, **J**=8Hz, 2H, CH benzimidazole) 7.49 (s, 1H, CH benzimidazole), MS m/z(%):247.14 , calcd.247

A solution of the appropriate secondary amine (0.05M), 2-((3-chloropropyl)thio)-1H-benzo[d]imidazole**20**or 5-chloro-2-<math>((3-chloropropyl)thio)-1H-benzo[d]imidazole**21**(0.05M) and unhydrous K<sub>2</sub>CO<sub>3</sub>(0.1M) in dry DMF(10 ml) was stirred in room temprature for 3- 24 hr. After compleation of reaction which was monitored by TLC, water and EA were added to the reaction mixture, EA layer was separated and dried by Na<sub>2</sub>SO4 and evaporated in vacuo affording a solid residue.

4.1.3.1. 4-(3-((*1H*-Benzo[d]imidazol-2-yl)thio)propyl)morpholine **22** Puff solid, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 2.3(p, 2H, CH<sub>2</sub>), 2.4-2.49(m, 8H, morphorine-H), 3.29(t, **J**=5.5Hz, 2H, N-CH<sub>2</sub>), 4.2(t, **J**=6Hz, 2H, S-CH<sub>2</sub>), 7.1-7.4(m, 4H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 22.8, 25.9, 39.5, 42.2, 43.1, 116.9, 121.7, 142.3, 146.5, MS m/z(%):277.39, calcd.277.4

4.1.3.2. 2-((3-(4-Methylpiperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **23** Puff solid ,m.p.=140 °c , yield=48% , <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 2.3(p, 2H, CH<sub>2</sub>), 2.4-2.49(m, 8H, piperazine-H), 3.28(t, J=5.75Hz, 2H, N-CH<sub>2</sub>), 3.3(s, 3H, N-CH2), 4.2(t, J=5.75Hz, 2H, S-CH<sub>2</sub>), 7.1-7.44(m,4H,CHbenzimidazole), <sup>13</sup>C NMR(150 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 23.3, 25.8, 40.07, 42.63, 109.1 (negative in APT), 117.4 (negative in APT), 121.1 (negative in APT), 122.2 (negative in APT), 136.1, 142.9, 146.9, MS m/z(%):290.43 , calcd.290.4

4.1.3.3. 2-((3-(Piperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **24** Puff solid, <sup>1</sup> H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.32(p, 2H, CH<sub>2</sub>), 2.4-2.87(m, 8H, piperazine-H), 3.35(t, 2H, N-CH<sub>2</sub>), 4.39(t, 2H, S-CH<sub>2</sub>), 7.11-7.45(m, 4H, CHbenzimidazole), <sup>13</sup>C NMR(150 MHz, DMSO-d<sub>6</sub>) δ: 23.3, 25.7, 42.69, 109.1 (negative in APT), 117.5 (negative in APT), 121.3 (negative in APT), 122.2 (negative in APT), 136.1, 142.9, 147, MS m/z(%):276.4, calcd.276.5

4.1.3.4. 2-((3-(4-(4-Methoxyphenyl)piperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **25** Puff solid <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.34(p,2H,CH<sub>2</sub>), 2.86-2.99(m,8H, piperazine -H), 3.28(t, **J**=5.55Hz, 2H,N-CH<sub>2</sub>), 3.673(s,3H,O-CH<sub>3</sub>), 4.2(t, **J**=6Hz, 2H, S-CH<sub>2</sub>), 6.82(d, J=8Hz, 2H, Ar-H), 6.9(d, J=8.2Hz, 2H, Ar-H), 7.1-7.45(m, 4H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:26.7, 34.6, 51.4, 52.8, 54.1, 56.1, 116.4, 118.1, 122.8, 138.9, 145.2, 147.6, 155.2, MS m/z(%):382.53, calcd.382.5

4.1.3.5. 2-((3-(4-(2-Ethoxyphenyl)piperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **26** Puff solid , <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.32(t, **J**=6.75Hz, 3H, CH<sub>3</sub>), 2.32 (p, 2H, CH<sub>2</sub>), 2.89-2.98(m, 8H, piperazine -H), 3.34(t, **J**=5.25Hz, 2H, N-CH<sub>2</sub>), 4(q, 2H, O-CH2), 4.2(t, **J**=5.75Hz, 2H, S-CH<sub>2</sub>), 6.85-6.95(m, 4H, Ar-H), 7.1-7.4(m, 4H, CHbenzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:14.8, 23.5, 29.9, 51.6, 53.1, 55.1, 63.6, 112.1, 115.2, 119.5, 120.1, 122.2, 123.4, 137.5, 142.6, 147.1, 162.3, MS m/z(%):396.55, calcd.396.6

4.1.3.6. 2-((3-(4-(3-Chlorophenyl)piperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **27** Puff solid, <sup>1</sup> H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.3(p, 2H, CH<sub>2</sub>), 2.49-2.6(m, 8H, piperazine -H), 3.3(t, J=5.75Hz, 2H, N-CH<sub>2</sub>), 4.2(t, J=5.75Hz, 2H, S-CH<sub>2</sub>), 6.82 (d, J=7.5Hz, 1H, Ar-H), 6.96(d, J=8.1, 1H, Ar-H), 7.02(s, 1H, Ar-H), 7.24(t, J=8Hz, 1H, Ar-H), 7.3-7.49(m, 4H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:27.2, 33.7, 51.1, 53.2, 55.1, 110.1, 113.5, 117.9, 122.8, 124, 131.6, 136.1, 138.9, 146.1, 147.6, MS m/z(%):386.94, calcd.387

4.1.3.7. 5-Chloro-2-((3-(4-methylpiperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **28** Brown solid, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.31 (p, 2H, CH<sub>2</sub>), 2.49-2.6(m, 8H, piperazine -H), 3.29(t, **J**=5.5Hz, 2H, N-CH<sub>2</sub>), 3.3(t, 3H, N-CH<sub>3</sub>), 4.2(t, **J**=5.75Hz, 2H, S-CH<sub>2</sub>), 7.15(d, **J**=8Hz, 1H, CH benzimidazole), 7.45(s, 1H, CH benzimidazole), 7.56(d, J=8Hz, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:26.8, 34.1, 47.9, 51.3, 53.1, 54.9, 116.1, 118.1, 122.2, 129.1, 138.1, 139.9, 146.3, MS m/z(%):324.87, calcd.324.9

4.1.3.8.5-Chloro-2-((3-(4-(2-ethoxyphenyl)piperazin-1-yl)propyl)thio)-1H-benzo[d]imidazole **29** Puff solid, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.33(t, **J**=6.75Hz, 3H, CH<sub>3</sub>), 2.31(p, 2H, CH<sub>2</sub>), 2.85-2.89(m, 8H, piperazine -H), 3.28(t, **J**=5.75Hz, 2H, N-CH<sub>2</sub>), 4.01(q, 2H, O-CH<sub>2</sub>), 4.2(t, **J**=5.25Hz, 2H, S-CH<sub>2</sub>), 6.83-6.89(m, 4H, Ar-H), 7.15(d, **J**=8Hz, 1H, CH benzimidazole), 7.45(s, 1H, CH benzimidazole), 7.5 (d, **J**=8Hz, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:15.9, 26.1, 33.9, 51.5, 55.2, 59.8, 112.9, 116.3, 118.2, 120.6, 120.9, 122.1, 125.2, 129.3, 138.4, 140.1, 145.6, 146.2, 147.9, MS m/z(%):431, calcd.431.1

4.1.3.9.5-Chloro-2-((3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)thio)-1H-benzo[d] imidazole **30** Puff solid, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 2.31(p,2H,CH<sub>2</sub>), 2.49-2.6(m, 8H, piperazine -H), 3.28(t, J=5.75Hz, 2H, N-CH<sub>2</sub>), 3.6(s, 3H, O-CH<sub>3</sub>), 4.2(t, J=6Hz, 2H, S-CH<sub>2</sub>), 7.15(d, J=8Hz, 2H, Ar-H), 7.173(d, J=8.2Hz, 2H, Ar-H), 7.43(s, 1H, CH benzimidazole), 7.48(d, J=8Hz, 1H, CH benzimidazole), 7.56(d, J=8Hz, 1H, CH benzimidazole), <sup>13</sup>C NMR(150 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 23.15, 25.69, 40.07, 42.9, 50.07, 55.58 (negative in APT), 109.42 (negative in APT), 110.34 (negative in APT), 114.63 (negative in APT), 116.93 (negative in APT), 118.5 (negative in APT), 121.17 (negative in APT), 122.36 (negative in APT), 126, 126.7, 134.9, 136.8, 141.6, 143.7, 148.4, 149, MS m/z(%):416.97, calcd.417

4.1.3.10.5-Chloro-2-((3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)thio)-1H-benzo[*d*] imidazole **31** Puff solid, <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ: 2.31(p,2H,CH<sub>2</sub>), 2.29-3.14(m,8H, piperazine-H), 3.29(t, J=5.75Hz, 2H,N-CH<sub>2</sub>), 4.2(t, J=5.75Hz, 2H, S-CH<sub>2</sub>), 6.76(d, J=7.5Hz, 1H, Ar-H), 6.88(d, J=8.1Hz, 1H, Ar-H), 6.91(s, 1H, Ar-H), 7.15(d, J=8Hz, 1H, CH benzimidazole), 7.43(t, J=8Hz, 1H, Ar-H), 7.45(s, 1H, CH benzimidazole), 7.57(d, J=8Hz, 1H, CH benzimidazole), <sup>13</sup>C NMR(100 MHz, DMSO-d<sub>6</sub>) δ:27.1, 34.3, 51.1, 53.2, 56.7, 112.2, 113.9, 115.7, 116.2, 120.9, 124.1, 129.1, 131.1, 136.1, 139.1, 140.5, 147.5, 149.9, MS m/z(%):421.38, calcd.421.4

# 4.2. Experimental NMR for Drug-Design

<sup>15</sup>N-labeled Pin1 was expressed and purified according to the known protocol [39,40]. The sample was concentrated to a final concentration of 200μM in PBS buffer at pH=6.5. Compounds number **5**, **12** and **25** were dissolved in DMSO and added to the protein to achieve a final concentration of 1mM in the NMR tube. <sup>15</sup>N-<sup>1</sup>H-HSQC experiments have been performed for the protein alone or with the compound on Varian-900MHz-cold probe in University of Colorado, Denver. The number of points used in the indirect dimension were 128 and with 32 scans. The spectra were processed using NMR Pipe [41] and figures were created using Sparky [42] software.

# 4.3. Cytotoxicity assay

Cell line: Mammary gland breast cancer (MCF-7). The cell line was obtained from ATCC via Holding company for biological products and vaccines (VACSERA), Cairo, Egypt. Doxorubicin was used as a standard anticancer drug for comparison. Chemical reagents: the reagents RPMI-1640 medium, MTT and DMSO (sigma co., St. Louis, USA), Fetal Bovine serum (GIBCO, UK) [43]. The cell line mentioned above were used to determine the inhibitory effects of compounds on cell growth using the MTT assay. Cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum. Antibiotics added were 100 units/ml penicillin and 100 $\mu$ g/ml streptomycin at 37 C in a 5% Co2 incubator. The cell lines were seeded in a 96-well plate at a density of 1.0x104 cells/well at 37 C for 48 h under 5% Co2. After incubation, the cells were treated with different concentration of compounds and incubated for additional 24h. After 24h of drug treatment, 20  $\mu$ l of MTT solution at 5mg/ml was added and incubated for 4h. Dimethyl sulfoxide (DMSO) in volume of 100  $\mu$ l is added into each well to dissolve the purple formazan formed. The absorbance was measured at wavelength 570 nm using a plate reader (EXL 800, USA). The relative cell viability in percentage was calculated as (A570 of treated samples/A570 of untreated sample) X 100 [44].

## 4.4. Apoptosis assay

Apoptosis detection was performed by using Annexin V-FITC and PI apoptosis kit (eBioscienceTM, San Diego, CA, USA). Mcf cells were plated at a 600000 cells/mL density onto a six well plate. After 24 h of incubation, the cells were treated with compound 15 at 10 Mg/mL. Cells grown in media containing an equivalent amount of DMSO served as the solvent control. After 24 h, the cells were stained with an Annexin V-FITC conjugate and propidium iodide (PI), and the percentage of apoptotic, necrotic, and living cells was determined according to the protocol provided by the Annexin V-FITC and PI apoptosis kit. The cells' emitted fluorescence was analyzed by flow cytometry (NovoCyte, ACEA Biosciences Inc, San Diego, CA, US) through the NovoExpress 1.3.0 software (ACEA Biosciences Inc, San Diego, CA, US), acquiring  $1 \times 104$  events per sample using the population plot "dot plot", where each point corresponds to a single event with a specific fluorescence signal in reference to the axes; Annexin V-FITC green fluorescence in abscissa vs. PE red fluorescence in ordinate.

## 4.5. Molecular modeling

The three-dimensional structures of some selected substituted benzimidazole **5**, **12**, **25** which represent best anti-breast cancer activity, in their neutral forms, were built by using the MOE of Chemical Computing Group Inc software 2014. The Lowest energy conformers of new analogues 'global-minima' was docked into the binding pocket of 4TYO pdb [45] It was

obtained from the Protein Data Bank of Brookhaven National Laboratory. The hydrogens were added, then enzyme structure was subjected a refinement protocol where the constraints on the enzyme were gradually removed and minimized until the RMSD gradient was 0.01 kcal/mol A°. Energy minimization was carried out using the molecular mechanics force field 'AMBER.' For each benzimidazole derivative, energy minimizations (EM) were performed using 1000 steps of steepest descent, followed by conjugate gradient minimization to a RMSD energy gradient of 0.01 Kcal/mol Å. The active site of the enzyme was detected using a radius of 10.0 Å around MTX. Energy of binding was calculated as the difference between the energy of the complex and individual energies of the enzyme and ligand [46, 47]. The compounds under study underwent flexible alignment experiment using 'Molecular Operating Environment' software (MOE of Chemical Computing Group Inc., on a Core i7 2.3 GHz workstation). The molecules were constructed using the Builder module of MOE. Their geometry was optimized by using the MMFF94 forcefield followed by a flexible alignment using systematic conformational search. The Lowest energy aligned conformers were identified. ADMET Calculations (Absorption, Distribution, Metabolism, Excretion, and Toxicity) were determined using implemented tool in MOE, 2014. Molecular structure of the tested flavonoids was constructed from fragment libraries MOE [48-50]. For each analogue, the partial atomic charges were assigned using the semi-empirical mechanical calculation ``AM1`` method implemented in the program [51]. Conformational search was done. All the conformers were minimized until the RMSD deviation was 0.01 Kcal/mol, then subjected to surface mapping, color coded: pink, hydrogen bond; blue: mild polar; green hydrophobic.

# Acknowledgements

The authors thank Alexandra Born and Professor Beat Vögeli for providing Pin1 enzyme and the magnet time at University of Colorado, Denver, USA.

# Declarations

The authors report no conflict of interest.

# References

 Ramla MM, Omar MA, El-Khamry A-MM and El-Diwani HI (2006) Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. BIOORGAN. MED. CHEM. 14:7324-7332.

- Abdel-Mohsen SA, El-Emary TI and El-Kashef HS (2016) Synthesis, Antiinflammatory and Antibacterial Activities of Novel Pyrazolo[4,3-g]pteridines. CHEM. PHARM. BULL. (Tokyo) 64:476-82. doi: 10.1248/cpb.c16-00044
- Sharma D, Narasimhan B, Kumar P, Judge V, Narang R, De Clercq E and Balzarini J (2009) Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. <u>EUR. J. MED. CHEM</u>. 44:2347-2353. doi: <u>https://doi.org/10.1016/j.ejmech.2008.08.010</u>
- Tonelli M, Simone M, Tasso B, Novelli F, Boido V, Sparatore F, Paglietti G, Pricl S, Giliberti G, Blois S, Ibba C, Sanna G, Loddo R and La Colla P (2010) Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. <u>BIOORGAN. MED. CHEM</u>. 18:2937-2953. doi: <u>https://doi.org/10.1016/j.bmc.2010.02.037</u>
- Göker H, Özden S, Yıldız S and Boykin DW (2005) Synthesis and potent antibacterial activity against MRSA of some novel 1,2-disubstituted-1H-benzimidazole-Nalkylated-5-carboxamidines. EUR. J. MED. CHEM. 40 .1069-1062:doi: https://doi.org/10.1016/j.ejmech.2005.05.002
- He Y, Yang J, Wu B, Risen L and Swayze EE (2004) Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents. BIOORG. MED. CHEM. LETT. 14:1 .1220-217doi: <u>https://doi.org/10.1016/j.bmcl.2003.12.051</u>
- Sharma S, Gangal S and Rauf A (2009) Convenient one-pot synthesis of novel 2substituted benzimidazoles, tetrahydrobenzimidazoles and imidazoles and evaluation of their *in vitro* antibacterial and antifungal activities. EUR. J. MED. CHEM. 44:1751-1757. doi: <u>https://doi.org/10.1016/j.ejmech.2008.03.026</u>
- 8. Kamala G, Srinivasan N, Shankar KR and Suresh R (2018) Synthesis, Characterization and Antimicrobial Evaluation of N-Mannich Bases of (2-Substituted Phenyl) Benzimidazole Derivatives. AJPR 8:87-93.
- Can NÖ, Acar Çevik U, Sağlık BN, Levent S, Korkut B, Özkay Y, Kaplancıklı ZA and Koparal AS (2017) Synthesis, Molecular Docking Studies, and Antifungal Activity Evaluation of New Benzimidazole-Triazoles as Potential Lanosterol 14α-Demethylase Inhibitors. J. CHEM-NY. 2017.
- Taha M, Mosaddik A, Rahim F, Ali S, Ibrahim M and Almandil NB (2018) Synthesis, antiglycation and antioxidant potentials of benzimidazole derivatives. J. KING SAUD UNIV. - SCI. doi: https://doi.org/10.1016/j.jksus.2018.04.003
- 11. Özil M, Parlak C and Baltaş N (2018) A simple and efficient synthesis of benzimidazoles containing piperazine or morpholine skeleton at C-6 position as glucosidase inhibitors with antioxidant activity. BIOORG. CHEM. 76:468-477. doi: https://doi.org/10.1016/j.bioorg.2017.12.019
- 12. Kanwal A, Saddique FA, Aslam S, Ahmad M and Zahoor AF (2018) Benzimidazole Ring System as a Privileged Template for Anticancer Agents. PHARM. CHEM. J.. 2018;51(12):1068-1077. DOI: 10.1007/s11094-018-1742-4
- Cheong JE, Zaffagni M, Chung I, Xu Y, Wang Y, Jernigan FE, Zetter BR and Sun L (2018) Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. EUR J. MED. CHEM. 144:372-385. doi: https://doi.org/10.1016/j.ejmech.2017.11.037
- Abonia, R.; Cortés, E.; Insuasty, B.; Quiroga, J.; Nogueras, M.; Cobo, J. Synthesis of novel 1,2,5-trisubstituted benzimidazoles as potential antitumor agents. EUR. J. MED. CHEM. 2011, 46, 4062–4070.
- 15. Kamal,A.;Reddy,T.S.;Vishnuvardhan,M.V.P.S.;Nimbarte,V.D.;Rao,A.V.S.;Srinivasul u,V.;Shankaraiah,N. Synthesis of 2-aryl-1,2,4-oxadiazolo-benzimidazoles: Tubulin

polymerization inhibitors and apoptosis inducing agents. **BIOORGAN. MED. CHEM**. 2015, 23, 4608–4623.

- Kamal, A.; Shaik, A.B.; Polepalli, S.; Kumar, G.B.; Reddy, V.S.; Mahesh, R.; Garimella, S.; Jain, N. Synthesis of arylpyrazole linked benzimidazole conjugates as potential microtubule disruptors. BIOORGAN. MED. CHEM. 2015, 23, 1082–1095.
- Husain, A.; Rashid, M.; Mishra, R.; Parveen, S.; Shin, D.-S.; Kumar, D. Benzimidazole bearing oxadiazole and triazolo-thiadiazoles nucleus: Design and synthesis as anticancer agents. BIOORG. MED. CHEM. LETT. 2012, 22, 5438–5444.
- 18. Rashid, M.; Husain, A.; Mishra, R. Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents. EUR J. MED. CHEM. 2012, 54, 855–866.
- 27. Husain, A.; Rashid, M.; Shaharyar, M.; Siddiqui, A.A.; Mishra, R. Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: New anticancer agents. EUR. J. MED. CHEM. 2013, 62, 785–798
- Dou Y-H, Xu S-D, Chen Y and Wu X-H (2017) Synthesis, characterization, and anticancer activity of dithiocarbamate ruthenium (II) complexes. PHOSPHORUS SULFUR 192:1219-1223.
- Buac D, Schmitt S, Ventro G, Rani Kona F and Ping Dou Q (2012) Dithiocarbamatebased coordination compounds as potent proteasome inhibitors in human cancer cells. MINI-REV. MED CHEM. 12:1193-1201.
- Cvek B , Dithiocarbamate complexes with metals in cancer therapy MINI-REV. MED. CHEM. 2012 Oct;12(12):1173.
- 23. Bala V, Gupta G and L Sharma V (2014) Chemical and medicinal versatility of dithiocarbamates: an overview. MINI-REV. MED. CHEM. 14:1021-1032.
- 24. Bacharaju K, Jambula SR, Sivan S, JyostnaTangeda S and Manga V (2012) Design, synthesis, molecular docking and biological evaluation of new dithiocarbamates substituted benzimidazole and chalcones as possible chemotherapeutic agents. BIOORG MED. CHEM. LETT. 22:3274-3277. doi: https://doi.org/10.1016/j.bmcl.2012.03.018
- Lu, K. P.; Hanes, S. D.; Hunter, T. A Human Peptidyl-Prolyl Isomerase Essential for Regulation of Mitosis. NATURE 1996, pp 544–547.
- Shen, M.; Stukenberg, P. T.; Kirschner, M. W.; Lu, K. P. The Essential Mitotic Peptidyl-Prolyl Isomerase Pin1 Binds and Regulates Mitosis-Specific Phosphoproteins. GENES DEV. 1998, 12 (5), 706–720.
- Liou, Y.-C.; Zhou, X. Z.; Lu, K. P. Prolyl Isomerase Pin1 as a Molecular Switch to Determine the Fate of Phosphoproteins. TRENDS BIOCHEM. SCI. 2011, 36 (10), 501– 514.
- Rajbhandari, P.; Finn, G.; Solodin, N. M.; Singarapu, K. K.; Sahu, S. C.; Markley, J. L.; Kadunc, K. J.; Ellison-Zelski, S. J.; Kariagina, A.; Haslam, S. Z.; et al. Regulation of Estrogen Receptor α N-Terminus Conformation and Function by Peptidyl Prolyl Isomerase Pin1. MOL. CELL BIOL. 2012, 32 (2), 445–457.
- Nicolas Baurin, #; Fareed Aboul-Ela; Xavier Barril; Ben Davis; Martin Drysdale; Brian Dymock; Harry Finch; Christophe Fromont; Christine Richardson; Heather Simmonite, and; et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. J. CHEM. INF. COMPUT. SCI 2004, 44, 6, 2157-2166
- Potter, A. J.; Ray, S.; Gueritz, L.; Nunns, C. L.; Bryant, C. J.; Scrace, S. F.; Matassova, N.; Baker, L.; Dokurno, P.; Robinson, D. A.; et al. Structure-Guided Design of α-Amino Acid-Derived Pin1 Inhibitors. BIOORG. MED. CHEM. LETT. 2010, 20 (2), 586–590.
- 31. Dong, L.; Marakovits, J.; Hou, X.; Guo, C.; Greasley, S.; Dagostino, E.; Ferre, R. A.;

Johnson, M. C.; Kraynov, E.; Thomson, J.; Pathak, V.; Murray, B. W. BIOORG. MED. CHEM. LETT. 2010, 20, 2210.

- 32. Ma, R.; Wang, P.; Wu, J.; Ruan, K. Process of Fragment-Based Lead Discovery—A Perspective from NMR. MOLECULES 2016, 21 (7), 854.
- 33. Byrne, C.; Henen, M. A.; Belnou, M.; Cantrelle, F. X.; Kamah, A.; Qi, H.; Giustiniani, J.; Chambraud, B.; Baulieu, E. E.; Lippens, G.; et al. A β-Turn Motif in the Steroid Hormone Receptor's Ligand-Binding Domains Interacts with the Peptidyl-Prolyl Isomerase (PPIase) Catalytic Site of the Immunophilin FKBP52. BIOCHEMISTRY 2016, 55 (38), 5366–5376.
- 34. (D.O. Cicero, G. Barbato, R. Bazzo, Sensitivity enhancement of a two-dimensional experiment for the measurement of heteronuclear long-range coupling constants, by a new scheme of coherence selection by gradients, J. MAGN. RESON. 148 (2001) 209– 213. <u>https://doi.org/10.1006/jmre.2000.2234</u>)
- 35. A. Bax, R.H. Griffey, B.L. Hawkins, Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR, J. MAGN. RESON. 55 (1983) 301–315. https://doi.org/10.1016/0022-2364(83)90241-X)
- 36. Samir Bondock, Shymaa Adel, Hassan A. Etman, Farid A. Badria. Synthesis and antitumor evaluation of some new 1,3,4-oxadiazole-based Heterocycles EUR. J. MED. CHEM. 48 (2012) 192e199
- 37. M.I. Thabrew, R.D. Hughes, I.G. McFarlane, J. PHARM. PHARMACOL. 49 (1997) 1132e1135
- Andrew J. Potter, Stuart Ray, Louisa Gueritz, Claire L. Nunns, Christopher J. Bryant, Simon F. Scrace, Natalia Matassova, Lisa Baker, Pawel Dokurno, David A. Robinson Allan E. Surgenor, Ben Davis, James B. Murray, Christine M. Richardson \_, Jonathan D. Moore Structure-guided design of a-amino acid-derived Pin1 inhibitors BIOORG. MED. CHEM. LETT. 20 (2010) 586–590.
- Born, A.; Henen, M.; Nichols, P.; Wang, J.; Jones, D.; Vogeli, B. Efficient Stereospecific Hβ2/3 NMR Assignment Strategy for Mid-Size Proteins. MAGNETOCHEMISTRY 2018, 4 (2), 25.
- Born, A.; Nichols, P. J.; Henen, M. A.; Chi, C. N.; Strotz, D.; Bayer, P.; Tate, S.-I.; Peng, J. W.; Vögeli, B. Backbone and Side-Chain Chemical Shift Assignments of Full-Length, Apo, Human Pin1, a Phosphoprotein Regulator with Interdomain Allostery. BIOMOL. NMR ASSIGN. 2018, 1–5.
- Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: A Multidimensional Spectral Processing System Based on UNIX Pipes. J. BIOMOL. NMR 1995, 6 (3), 277–293.
- 42. Lee, W.; Tonelli, M.; Markley, J. L. NMRFAM-SPARKY: Enhanced Software for Biomolecular NMR Spectroscopy. BIOINFORMATICS 2015, 31 (8), 1325–1327.
- T.Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. IMMUNOL. METHODS 65 (1983) 55-63 DOI: 10.1016/0022-1759(83)90303-4
- F. Denizot, and R. Lang. Rapid colorimetric assay for cell growth and survival. J. IMMUNOL. METHODS. 89:271–277 (1986).
- 45. Guo, C., Hou, X., Dong, L., Marakovits, J., Greasley, S., Dagostino, E., Ferre, R., Catherine Johnson, M., Humphries, P.S., Li, H., Paderes, G.D., Piraino, J., Kraynov, E., Murray, B.W. Structure-based design of novel human Pin1 inhibitors (III):

Optimizing affinity beyond the phosphate recognition pocket. 4TYO (2014) BIOORG. MED. CHEM. LETT. 24: 4187-4191

- 46. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. ADV. DRUG DELIVER. REV. 23 (1997) 3-25.
- 47. S. Profeta, N.L. Allinger, Molecular mechanics calculations on aliphatic amines. JACS 107 (1985) 1907-1918.
- 48. N. L. Allinger. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms JACS 99 (1977) 8127-8134.
- P. Labute, C. Williams, M. Feher, E. Sourial, J.M. Schmidt, Flexible alignment of small molecules. J. MED. CHEM. 44 (2001) 1483–1490.
- S. Kearsley, G.M. Smith. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap. TETRAHEDRON COMPUT. METHODOL. 3 (1990) 615–633.
- Cornell, W. D., Cieplak, P., Bayly, C. I., Gould, I. R. et al., A second Generation forth field for the simulation of Proteins and Nucleic Acids. JACS 1995, 117, 5179-5197

Figure 1: An overlay of <sup>13</sup>C-<sup>1</sup>H HMBC (magenta) with <sup>13</sup>C-<sup>1</sup>H HSQC (green) of compound 10 (top) & compound 15 (bottom). Peaks that were of particular interest to verify the structure are annotated on top of each peak. HSQC peaks of interest are highlighted by red letter. HMBC peaks showing long-range connections are highlighted by blue roman numbers.

Figure 2: Viability of MCF-7 cell line at various concentrations

Figure 3: Left: Percent of DNA content in compound 15 treated cells vs the control at different cell cycle phases. Right: Percent of apoptotic cells in compound 15 treated cells vs control (total, early, late and necrosis).

Figure 4: Evaluation of apoptosis induced by compound 15 treatment. Flow cytometry analysis for Annexin-VFITC/PI staining Left: compound 15 treated cells, right: control.

Figure 5: Overlay of <sup>15</sup>N-<sup>1</sup>H HSQC spectra of free Pin1 enzyme (red) with Pin1 bound to: Compound 5 (violet), compounds 12 (green), and compound 25 (blue). The overlay is showing chemical shift perturbation and peak disappearance for different peaks as indicative of binding on different time scales.

Figure 6: Lowest energy conformers of compounds 5, 12 and 25 with balls and cylinders

Figure 7: 2D binding mode and residues involved in the recognition of reference ligand 3-(6-fluoro-1H-benzimidazol-2-yl)-N-(naphthalen-2-ylcarbonyl)-D-alanine (Arg69, Phe143, Ser115, Lys63, Cys113 (with yellow highlight).

Figure 8: 2D binding mode and residues involved in the recognition of Compounds 5 and 12 ligands as references at Pin1 enzyme.

- Figure 9: (a) 2D binding mode and residues involved in the recognition of active compound 25 at Pin1 enzyme. (b) The aligned conformation of compound 25 (ball and stick) occupying pocket (surface mapping).
- Figure 10: Contact statistics map for compounds 5, 12 and 25 (hydrophobic: green, hydrophilic: red)
- Figure 11: Surface map for compounds 5, 12 and 25, Pink, hydrogen bond, blue: mild polar, green hydrophobic

Scheme 1. Synthesis of the target compounds 5-15

- Scheme 2. Synthesis of the target compounds 21-31
- Chart 1. Structures of some literature benzimidazoles with anti-proliferative activity against breast cancer cell lines. LC50 reported for these compounds against MCF7 is >100µM.
- Chart 2: Structures of some benzimidazole and its isosteres as Pin1 inhibitors & the target compounds as well as the rational design.

Table 1. Physicochemical properties of the newly synthesized compounds 5-15 and 21-31



Comp	X	<b>R</b> <sup>1</sup>	R <sup>2</sup>	R	% Yield	Mp, °C	Molecular Formulae
5	0	Cl	Cl	Н	20	171-173	$C_{13}H_{13}Cl_2N_3OS_2$
6	CH <sub>2</sub>	Cl	Cl	Н	48	216-218	$C_{14}H_{15}Cl_2N_3S_2$
7	-	Cl	Cl	$NH(C_2H_5)_2$	45	117-119	$C_{13}H_{15}Cl_2N_3S_2$

0111110	Dro nro	ota
00011101	$\mathbf{I}$	

8	N	Cl	Cl	$2-OC_2H_5-C_6H_4$	50	110-112	$C_{21}H_{22}Cl_2N_4OS_2$	
9	N	Cl	Cl	4-CH <sub>3</sub>	30	205-207	$C_{14}H_{16}Cl_2N_4S_2$	
10	N	Cl	Cl	$4-OCH_3-C_6H_4$	40	220-222	$C_{20}H_{20}Cl_2N_4OS_2$	
11	N	Cl	Cl	3-Cl-C <sub>6</sub> H <sub>4</sub>	30	135-137	$C_{19}H_{17}Cl_3N_4S_2$	
12	CH <sub>2</sub>	CH <sub>3</sub>	CH <sub>3</sub>	Н	19	188-190	$C_{16}H_{21}N_3S_2$	
13	Ν	CH <sub>3</sub>	CH <sub>3</sub>	4-OCH <sub>3</sub>	39	104-106	$C_{22}H_{26}N_4OS_2$	
14	N	CH <sub>3</sub>	CH <sub>3</sub>	3-Cl-C <sub>6</sub> H <sub>4</sub>	15	77-79	$C_{21}H_{23}ClN_4S_2$	
15	N	CH <sub>3</sub>	CH <sub>3</sub>	-2-OC <sub>2</sub> H <sub>5</sub> - <sub>6</sub> H <sub>4</sub>	40	93-95	$C_{23}H_{28}N_4OS_2$	
21		Cl	-	-	36	128-130	$C_{10}H_{10}Cl_2N_2S$	
22	0	Н	-	Н	67	136-138	C <sub>14</sub> H <sub>19</sub> N <sub>3</sub> OS	
23	N	Н	-	4-CH <sub>3</sub>	48	145-147	$C_{15}H_{22}N_4S$	
24	N	Н	-	Н	41	138-140	$\mathrm{C}_{14}\mathrm{H}_{20}\mathrm{N}_{4}\mathrm{S}$	
25	N	Н	-	$4-OCH_3-C_6H_4$	24	110-112	C <sub>21</sub> H <sub>26</sub> N <sub>4</sub> OS	
26	N	Н	-	$2-OC_2H_5-C_6H_4$	23	129-130	C <sub>22</sub> H <sub>28</sub> N <sub>4</sub> OS	
27	N	Н	-	3-Cl-C <sub>6</sub> H <sub>4</sub>	15	133-135	$C_{20}H_{23}ClN_4S$	
28	N	Cl	-	4-CH <sub>3</sub>	29	158-160	$C_{15}H_{21}ClN_4S$	
29	N	Cl		$2-OC_2H_5-C_6H_4$	15	149-151	C <sub>22</sub> H <sub>27</sub> ClN <sub>4</sub> OS	
30	Ν	Cl	_	$4-OCH_3-C_6H_4$	39	156-158	C <sub>21</sub> H <sub>25</sub> ClN <sub>4</sub> OS	
31	N	Cl	_	3-Cl-C <sub>6</sub> H <sub>4</sub>	19	126-128	$C_{20}H_{22}\overline{Cl_2N_4S}$	

 Table 2: DNA/methyl green colorimetric assay of the target compounds

IC<sub>50</sub> (μM): 1 – 10 (very strong). 11 – 20 (strong). 21 – 50 (moderate) 51 – 100 (weak) and above100 (noncytotoxic) • • **DOX**: Doxorubicin

Table 3	Compounds	<i>In vitro</i> Cytotoxicity IC50 (μM) • MCF7	Evaluation of
DNA content	DOX••	4.17±0.2	and apoptosis
induced by	5	5.70±3.3	compound 15
control.	6	42.75±2.8	cens miles vs
	7	12.55±1.1	
	8	16.23±1.4	
	9	30.47±2.3	
	10	19.93±1.7	
	11	60.20±3.8	
	12	9.55±0.9	
	13	46.03±3	
	14	8.39±0.7	
	15	5.58±0.3	
	21	24.07±1.9	
	22	82.87±4.8	
	23	77.92±4.1	
	24	91.69±5.2	
	25	6.84±0.5	
-	26	32.73±2.4	
	27	54.63±3.5	
	28	13.92±1.2	
	29	27.73±2.1	
		38.46±2.6	
	31	61.40±3.9	

			DNA content %				
Sample	Code	MWt	<mark>%G0-G1</mark>	<mark>%S</mark>	<mark>%G2-M</mark>	<mark>%Pre G1</mark>	Comment
1	s15/mcf7	440.62 g/mole	39.72	32.42	27.86	27.28	Cell growth arrest at G2/M
2	Control mcf7		56.38	38.15	5.47	1.04	

			<mark>Apoptosis</mark>			Necrosis
			Total	<mark>Early</mark>	Late	
1	s15/mcf7	440.62 g/mole	27.28	7.36	17.01	2.91
2	Control mcf7		1.04	0.41	0.19	0.44